Modafinil has lately received interest in the area of sleep medicine due to its capacity to induce alertness. As a result, modafinil has the potential to be an essential treatment for the excessive diurnal somnolence (EDS) that may accompany sleep disorders such as narcolepsy, sleep apnea, idiopathic hypersomnolence, and other medical illnesses defined by poor sleep quality and or quantity.
The Modalert Modafinil has been used to treat narcolepsy and idiopathic hypersomnolence in Europe since at least 1988. Modafinil was licensed by the US Food and Drug Administration in December 1998 after two major, multicenter trials.
Get More Info
Modafinil's mechanism of action is still a bit of a mystery. Although modafinil increases alertness, it is neither chemically nor pharmacologically linked to another central nervous system (CNS) stimulants that promote wakefulness, such as amphetamine or methylphenidate. Modafinil lacks the dopaminergic action associated with stimulants to which patients are prone to tolerance, and it is classified as a schedule IV drug with limited risk for misuse. It is more site-specific than other CNS stimulants, working in distinct brain regions (the hypothalamus and subcortical areas involved in the control of waking and sleep). Its ability to promote wakefulness necessitates the presence of a functional a1-adrenergic system.